@inproceedings{inproceedings, title  = {{Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.23.00943 }},

 year = {{2024}},

 month = {{1}},

 author = {{Russell NH and Wilhelm-Benartzi C and Othman J and Dillon R and Knapper S and Batten LM and Canham J and Hinson EL and Betteridge S and Overgaard UM and Gilkes A et al}},

 doi = {{10.1200/jco.23.00943}},

 volume = {{42}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{10}},

 pages = {{1158-1168}},

 note = {{Accessed on 2024/12/28}}}